Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (14760)	9/19/2000 11:32:32 PM
From: Robert K.	Respond to of 17367

Cacaito, re my comment> "you know Cacaito, I read the article, and I have a hard time believing that ANY medical professional would not think the data showed bpi to be of benefit. I dont doubt your training one bit, but I have severe reservations about your standards. I personally think it would be negligence to deny this drug if available even as a experimental " In spite of our "being at odds" often, I have a newfound respect for you. You reconsidered the NEW facts, and made a correct call (IMO of course). Besides, I always knew you where brilliant. I always said so.

To: Cacaito who wrote (14760)	9/20/2000 5:51:59 AM
From: Robert K.	Read Replies (2) \| Respond to of 17367

I will repeat again. Baxter KNEW the data BEFORE doing the deal. As did others. Baxter jumped higher. Baxter has said on record the potential of bpi(if successful in meningo) was far in excess of 500mil, xoma has said all along that bpi shows a benefit. Xoma does say trauma didnt work. Xoma is a quiet and secretive company at times. Xoma caution is sometimes interputed as failure. The data is the data. As I have said all along, the data will speak. The data has spoken. I believe the FDA will do the right thing (thats a guess of mine). I am fustrated that delays equal causualties. I hope the process "does right" in a speedy manner. end.